Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells

Molecular Cancer Therapeutics

Volumn 10, Issue 3, 2011, Pages 518-530

  Liu, Li ^a   Shi, Hong ^a   Liu, Yuan ^a   Anderson, Amber ^a   Peterson, John ^a   Greger, James ^a   Martin, Anne Marie ^a   Gilmer, Tona M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FORETINIB; GSK 1363089 G; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANILIDES; ANTIBODIES, MONOCLONAL; APOPTOSIS; DRUG SYNERGISM; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOPRECIPITATION; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79955781270     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0698     Document Type: Article

References (39)

1. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9. (Pubitemid 43166034)
2. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902. (Pubitemid 29202761)
3. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004;172:1256-61. (Pubitemid 39249692)
4. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, et al. Only a subset of met-activated pathways are required to sustain oncogene addiction. Sci Signal 2009;2:ra80.
5. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010:277:301-8.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
8. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82. (Pubitemid 40038747)
9. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 2008;7:9.
10. Tolgay O I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003;97:1841-8. (Pubitemid 36397257)
11. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol 2007;28:36-44. (Pubitemid 46012464)
12. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009-16.
13. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
14. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008;13:1114-9.
15. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
16. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-94. (Pubitemid 47063294)
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Peterson JJ, Novick SJ. Nonlinear blending: a useful general concept for the assessment of combination drug synergy. J Recept Signal Transduct Res 2007;27:125-46. (Pubitemid 47024328)
19. Peterson J. A review of synergy concepts of nonlinear blending and dose-reduction profiles. Front Biosci 2010;S2:483-503.
20. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
21. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8. (Pubitemid 46424226)
22. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17. (Pubitemid 46815090)
23. Taher TE, Tjin EP, Beuling EA, Borst J, Spaargaren M, Pals ST. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002;169:3793-800.
24. Sheth PR, Watowich SJ. Biochemical ground-rules regulating c-MET receptor tyrosine kinase activation and signaling. Cancer Therapy 2005;3:1-12.
25. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55. (Pubitemid 37413476)
26. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936-41.
27. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-5.
28. Kubo T, Kuroda Y, Shimizu H, Kokubu A, Okada N, Hosoda F, et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 2009;30:1857-64.
29. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006;25:409-18. (Pubitemid 43117626)
30. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
31. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. HumPathol 2007;38:830-41. (Pubitemid 46726507)
32. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L, et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 2007;96:329-35. (Pubitemid 46160639)
33. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997;65:195-203. (Pubitemid 27472525)
34. Nakamura Y, Matsubara D, Goto A, Ota S, Sachiko O, Ishikawa S, et al. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 2008;99:14-22. (Pubitemid 350239026)
35. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009;15:3740-50.
36. Turke AB, Zejnullahu K, Wu YL, Song Y, as-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
37. Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009;100:941-9.
38. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007;13:675-7. (Pubitemid 46889747)
39. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin Cancer Res 2008;14:2895-9.